Partner With VistaraBio
Mechanistic precision for therapeutic pipelines. Novel Assays. Screening platforms. Validation. Degrader safety.
Partnership Models
Mechanistic discovery, degrader co-development, small-molecule programs, peptide therapeutics, and assay access.
Fee-for-service or Partnering models.
we will help with your drug discovery research utilizing our platforms in-house.
What Partners Gain
Mechanistic derisking, accelerated discovery, precision design, and translational biomarkers.
Pipeline Overview
Mechanism-driven programs across degraders, small molecules, peptides, and assays.
Degrader Programs
CRBN glue discovery, Parkin glue exploration, context-specific glue mapping.
Small Molecule Programs
BRD4 kinase inhibitors, SUMO-switch modulators, JAK-STAT regulators.
Peptide Therapeutic Programs
Parkin cohort restoration, PD PTM-corrective peptides, proteostasis signature modulators.
Assay Platform Programs
TSA-CRBN, BRD4 kinase screening, MG-OS, PD PTM assays.
Mechanistic Stage-Gating
Substrate logic → PTM architecture → cohort assembly → glue/catalytic consequence → biomarkers.